ImageneBio/$IMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImageneBio
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Ticker
$IMA
Sector
Primary listing
Employees
15
Headquarters
Website
ImageneBio Metrics
BasicAdvanced
$55M
-
-$9.64
-
-
Price and volume
Market cap
$55M
52-week high
$17.96
52-week low
$3.94
Average daily volume
32K
Financial strength
Current ratio
12.488
Quick ratio
12.048
Long term debt to equity
0.536
Total debt to equity
2.235
Profitability
EBITDA (TTM)
-48.052
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,668.63%
Operating margin (TTM)
-6,056.38%
Effective tax rate (TTM)
0.77%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-35.86%
Return on equity (TTM)
-68.91%
Valuation
Price to revenue (TTM)
33.286
Price to book
0.41
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.557
Free cash flow yield (TTM)
-179.68%
Free cash flow per share (TTM)
-8.807
Growth
Revenue change (TTM)
-77.14%
Earnings per share change (TTM)
-56.36%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImageneBio stock?
ImageneBio (IMA) has a market cap of $55M as of April 12, 2026.
What is the P/E ratio for ImageneBio stock?
The price to earnings (P/E) ratio for ImageneBio (IMA) stock is 0 as of April 12, 2026.
Does ImageneBio stock pay dividends?
No, ImageneBio (IMA) stock does not pay dividends to its shareholders as of April 12, 2026.
When is the next ImageneBio dividend payment date?
ImageneBio (IMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ImageneBio?
ImageneBio (IMA) does not currently have a Beta indicator.